Novo Nordisk has announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment with concizumab in people living with haemophilia A or B.
The results from the primary analysis were presented at the International Society of Thrombosis and Haemostasis Annual Congress in London.
Concizumab is an anti-tissue factor pathway inhibitor antibody in development for once-daily prophylactic treatment by administration under-the-skin for all types of haemophilia.
The results showed an 86% reduction in treated spontaneous and traumatic bleeds when on concizumab prophylaxis. The safety and tolerability profile of the treatment was also within the expected range, with no thromboembolic events reported after the treatment was restarted.
“One of the most critical complications in the treatment of haemophilia is the development of inhibitors, as they render standard replacement therapy ineffective and severely limit treatment options for haemophilia B,” reflected explorer7 lead investigator Dr Victor Jiménez-Yuste.
He added: “Based on the results of the explorer7 study, there is a potential for concizumab to become a new treatment option for people living with haemophilia A or B with inhibitors.”
“The treatment of haemophilia is complex and no one treatment fits all,” added Martin Lange, executive vice president and head of development at Novo Nordisk. “Concizumab offers the potential for everyday protection for people living with haemophilia and provides an important potential addition to our haemophilia offering, especially in the haemophilia B with inhibitor population who currently have limited treatment options.”
Novo Nordisk expects to submit concizumab for regulatory approval for the prophylactic treatment of haemophilia A or B with inhibitors in the second half of 2022 in the US and Japan and – in 2023 – the EU and the UK.
The use of concizumab is currently investigational and not approved by regulatory authorities.
by John Pinching
Source: pharmatimes.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
